GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Notes Receivable

Accelerated Pharma (Accelerated Pharma) Notes Receivable : $0.00 Mil (As of Mar. 2017)


View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Notes Receivable?

Accelerated Pharma's Notes Receivable for the quarter that ended in Mar. 2017 was $0.00 Mil.


Accelerated Pharma Notes Receivable Historical Data

The historical data trend for Accelerated Pharma's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Notes Receivable Chart

Accelerated Pharma Annual Data
Trend Dec14 Dec15 Dec16
Notes Receivable
- - -

Accelerated Pharma Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Notes Receivable Get a 7-Day Free Trial - - - - -

Accelerated Pharma Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Accelerated Pharma Notes Receivable Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Accelerated Pharma (Accelerated Pharma) Business Description

Traded in Other Exchanges
N/A
Address
Website
Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines